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Abstract
Background
Breast cancer is the most frequent cancers and is the second leading cause of cancer
death among women. Trastuzumab is an effective treatment, the first monoclonal antibody
directed against the human epidermal growth factor receptor 2 (HER2). To inform the devel-
opment of other effective treatments we report summary estimates of efficacy of trastuzu-
mab on survival and tumour volume in animal models of breast cancer.
Methods
We searched PubMed and EMBASE systematically to identify publications testing trastuzu-
mab in animal models of breast cancer. Data describing tumour volume, median survival
and animal features were extracted and we assessed quality using a 12-item checklist. We
analysed the impact of study design and quality and evidence for publication bias.
Results
We included data from 83 studies reporting 169 experiments using 2076 mice. Trastuzu-
mab treatment caused a substantial reduction in tumour growth, with tumours in treated ani-
mals growing to 32.6% of the volume of tumours in control animals (95%CI 27.8%-38.2%).
Median survival was prolonged by a factor of 1.45 (1.30–1.62). Many study design and qual-
ity features accounted for between-study heterogeneity and we found evidence suggesting
publication bias.
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Conclusion
We have found trastuzumab to be effective in animal breast cancer models across a range
of experimental circumstances. However the presence of publication bias and a low preva-
lence of measures to reduce bias provide a focus for future improvements in preclinical
breast cancer research.
Introduction
Breast cancer is the second most common cancer in the world. With an estimated 1.67 million
new cancer cases diagnosed in 2012, breast cancer is the most frequent cancer and second lead-
ing cause of cancer death among women [1]. Treatment options including surgery, radiation
therapy, and systemic therapy have improved the survival and quality of life of breast cancer
patients over the past 30 years [2]. Targeted therapies, which selectively focus on specific
molecular targets on tumour cells, provide potential to improve survival and quality of life and
to reduce drug side effects [3, 4].
The human epidermal growth factor receptor-2 (HER2), overexpressed in between 15% and
20% of breast cancers [5], is one of the most common molecular targets for targeted therapies
[2]. Described as a proto-oncogene, HER2 expression in human cancer was first observed dur-
ing screening of DNA samples derived from breast cancers [6]. HER2 gene amplification sig-
nificantly predicts both reduced overall survival and shorter time to relapse in patients with
breast cancer. Higher expression of HER2 is associated with a more aggressive disease course
leading to worse clinical outcomes [6] as well as adverse prognostic features including
advanced pathologic stage [7] and number of metastatic axillary lymph nodes [8]. As a predic-
tor of risk of occurrence and response to therapy HER2 testing is recommended in pathology
examination for all newly diagnosed invasive breast cancer and first recurrences of breast can-
cer [5, 9] as part of to inform staging and choice of therapy.
Trastuzumab, also known as Herceptin, is the first monoclonal antibody directed against
HER2. Following studies in tumour xenografts showing that murine monoclonal antibody
(MAb) 4D5 inhibits the proliferation of human breast cancer cells overexpressing the HER2
receptor [10], trastuzumab was created in 1990 by humanizing the 4D5 mouse antibody to
overcome immunogenicity issues [11]. Subsequent first-generation clinical trials demonstrated
prolonged survival and time to progression in patients with HER2-positive metastatic breast
cancer [12]. As such, trastuzumab has been widely promoted and recommended for HER2-po-
sitive breast cancer in combination with chemotherapies such as cisplatin, doxorubicin or pac-
litaxel [13–15]. Several studies reported improved disease-free and overall survival following 1
year of trastuzumab administered concomitantly or sequentially as an adjuvant to chemother-
apy [16]. Furthermore, trastuzumab shows some efficacy when administrated as a single agent
in first-line treatment [17].
Trastuzumab has been used clinically for breast cancer since the mid-1990s and experience
in humans has been summarised in systematic reviews and meta-analyses [18, 19]. However,
efficacy in animal models has not been well characterised and the extent to which animal stud-
ies reliably informed early clinical trials is unclear. Animal experiments improve our under-
standing of disease mechanisms and they are invaluable for clinical research, ultimately
informing decisions on when to proceed to clinical trial. Systematic review and meta-analysis
of such studies may aid in the selection of the most promising treatment strategies for future
clinical trials, as well as in the identification of potential sources of bias arising from limitations
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in study design [20]. In the context of treatments known to be effective in humans, a deeper
understanding of these strengths and weaknesses of in vivo studies may inform the develop-
ment of new therapies. The Collaborative Approach to Meta-Analysis and Review of Animal
Data in Experimental Studies (CAMARADES) group have shown—for a range of experimental
neurological diseases including glioma, stroke and multiple sclerosis—that reporting of mea-
sures to reduce risk of bias (such as randomisation and blinding) is poor and that publication
bias is frequently present. These factors lead to a significant overstatement of perceived treat-
ment efficacy [21–23].
Therefore, we aimed to undertake a systematic review of trastuzumab in animal models of
breast cancer, to summarise the effect of trastuzumab on survival and tumour volume. We also
sought to describe the impact on observed efficacy of study quality features such as randomiza-
tion and blinding and experimental design features such as drug dose, timing of treatment, spe-
cies, study quality, so that we might ascertain the value of such studies in predicting clinical
efficacy and suggest how future animal research might be streamlined to predict clinical effi-
cacy more reliably.
Materials and Methods
The study was conducted in accordance with a protocol, first published online in December
2014 at http://www.dcn.ed.ac.uk/camarades/research.html#protocols.
Search strategy
We searched PubMed and EMBASE on 4 July 2013, using the terms relating to (breast tumor
OR breast cancer) AND (trastuzumab OR Herceptin) (S1 Table). On 18 September 2014, we
added three further terms to expand the search with previous names of trastuzumab: (breast
tumor OR breast cancer) AND ("rhuMAb HER2" OR "Anti-p185HER2 Monoclonal Antibody"
OR "muMAb 4D5”). For EMBASE the search was limited to animals, and for PubMed we used
a validated animal search filter [24]. Studies in all languages were accepted.
Study selection
Two investigators independently screened all titles and abstracts to identify studies meeting the
inclusion criteria. The full text of all these potentially eligible studies were retrieved and inde-
pendently assessed for eligibility by two investigators (Canhong Yang and Bin Guo), disagree-
ments were discussed with a third investigator (Jiarong Chen) after full text reading. We
included controlled studies that reported the efficacy of trastuzumab monotherapy in labora-
tory animals with induced breast cancer. We included studies reporting outcome as either
median survival or tumour volume in treatment and control groups. Publications had to state
the number of animals per group, and we excluded Reviews, Books, Letters, Clinical trials, Case
reports, or Editorials.
Data extraction
We extracted data to the CAMARADES data manager (Microsoft Access) for assessment of
study quality and evidence synthesis. Extracted information included: article information (title,
author, journal, publication year); agent for treatment and control group; trastuzumab treat-
ment (dose, total dose and frequency, route of administration, delay to treatment); tumour
volume data for treatment and control group (original tumour size included, measurement
method and frequency, measurement day after treatment, measurement day after tumour
implantation), and whether the study reported the blinded assessment of outcome. We
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recorded data from the last time point for tumour volume measurement for treatment and con-
trol group; median survival data for treatment and control group; experimental animals (num-
ber of animals for every group, species and strain, age, sex and original weight), breast cancer
model (breast cancer cell type, HER2 expression level (as determined by in situ hybridization
(ISH), immunology and histology chemistry (IHC), western blot or by other means), trastuzu-
mab resistance, tumour implantation method and implantation site, number or volume of
implanted tumour cells, use of estradiol (dose, route of administration, delay to treatment).
Missing data were requested from study authors. We extracted trastuzumab dose as mg/kg.
Where this was quoted as μg, we estimated a weight-adjusted dose based on a typical average
mouse weight of 25g.
Risk of bias
Two review authors independently assessed the risk of bias in included studies by consider-
ing the following characteristics: peer-reviewed publication, and reporting of random alloca-
tion of tumour-bearing animal to treatment or control groups, blinded assessment of
outcome, sample size calculation, statement of potential conflict of interests, compliance
with animal welfare policy, explanation of rationale for disease model used, or multiple
tumour models used, standardised number or volume of tumour cells implanted, reported
number of animals in which the tumour did not grow, reporting and explanation of excluded
animals, presentation of evidence that trastuzumab acts directly against the tumour, and con-
sistent implantation site. We collated these into a quality checklist, similar to that described
previously [21].
Analysis
1) Volume data. We initially intended to log transform the dataset (to account for expo-
nential tumour growth) and then generate a normalized mean difference summary statistic
(see protocol). However, through late 2014-early 2015 (after the data extraction phase) we
observed that this produced nonparametrically distributed data and, with a large number of
studies reporting improvements greater than +90%, there was a resultant skew with a large
number of studies clustered close to the ceiling efficacy of +100%. This effect persisted even if
the data were log transformed as planned a priori. Following discussion we instead decided to
use a volume ratio summary statistic, as when log-transformed this would produce parametri-
cally distributed data without ceiling. We elected to adopt the method suggested by Higgins
et al [25]. We have expressed volume ratio values as the inverse log of these summary estimates
to make the data easier to understand, and present these such that values over 1 favour the
treatment group to make interpretation of figures more intuitive.
We used DerSimonian and Laird random effects meta-analysis to pool studies and stratified
meta-analysis to search for sources of heterogeneity. For each group we again present the
inverse log to give more intuitive values for mean and SE. As we have stratified the volume data
13 times, we used Bonferroni correction to give a critical value for significance of p<0.00385.
2) Survival data. We generated an effect score of median survival ratio by dividing the
treated group by control group. We then log-transformed the data and used a modified form of
DerSimonian and Laird meta-analysis (weighted by the number of animals in the study instead
of inverse variance) to generate a global efficacy estimate [26]. We used stratified meta-analysis
as above.
3) Publication bias. We used funnel plots, Egger regression and Trim and Fill analysis
[27] to search for evidence of publication bias.
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Results
Identification of papers
We identified 1651 publications (PubMed 741, EMBASE 910), with 1299 articles remaining
after duplicate removal. After title and abstract screening, full texts of 269 articles were
retrieved. We found 85 studies reporting outcome as either median survival or tumour volume,
but one study was excluded because tumour size was only inferred by measuring the activity of
secreted molecules in the blood; tumour volume was measured directly in other studies. A fur-
ther experiment was excluded during the analysis stage as the control group was treated with
androstenedione, an androgen known to affect breast tumour growth in its own right [28].
Thus we included 83 studies reporting 169 experiments using 2076 mice in our meta-analysis
(Fig 1). No experiments used other species (See S2 Table).
We have generated a spreadsheet containing the raw data extracted from each publication
and published this on Figshare for public access (https://figshare.com/articles/Trastuzumab_
preclinical_SRMA_-_raw_dataset/3406513).
Of these, 158 experiments assessed tumour volume as the outcome measure, with 11 report-
ing animal survival. Trastuzumab treatment was associated with a substantial reduction in
tumour growth—with control tumours growing to 3.07 times the volume of treated tumours
(95%CI 2.62–3.60). That is, tumour volume in treated animals was reduced by 67.4% (95%CI
61.8% - 72.2%). We observed considerable between-study heterogeneity (χ2 = 11376, df = 157,
p<0.00385; I2 = 98.6%). Median survival was prolonged by a factor of 1.45 (1.30–1.62)
although we did not observe any between-study heterogeneity in this smaller dataset (χ2 = 6.0,
df = 10, p>0.05). Consequently we did not conduct a stratified meta-analysis of survival data.
Risk of bias
Study quality was evaluated based on a modified 12-point checklist [21] with a median quality
score of 6 (IQR 5–7; range 3 to 9. S3 Table). All of the 83 papers were published in a peer-
reviewed journal, 36 (43%) reported random allocation to group, 36 (43%) stated whether a
potential conflict of interest existed, and 31 (37%) described compliance with animal welfare
policy. 49 (59%) studies compared more than one model, and 69 (83%) presented evidence
that trastuzumab acts directly against the tumour. Standardized number or volume of tumour
cells implanted was reported in 78 (94%) studies, and implantation site was consistent in 71
(86%) of studies. The number of animals in which the tumour did not grow was reported in
only 4 (5%) studies and explanation of excluded animals was recorded in 12 (14%) studies. Sur-
prisingly, none of the studies described the blinded outcome assessment or reported a sample
size calculation. Stratification by the number of study quality checklist items scored accounted
for significant heterogeneity between studies (χ2 = 1373, df = 6, p<0.00385), with higher qual-
ity studies reporting lower efficacy (Fig 2a). Similarly, studies that randomized group allocation
reported lower efficacy (χ2 = 68.1, df = 1, P<0.00385. Fig 2b).
We also found substantial evidence of publication bias indicative of an overestimation of
observed efficacy and implying an absence of small, inefficacious studies in the literature.
Inspection of a funnel plot for tumour volume data suggests an excess of imprecise studies
reporting high efficacy; there were only 14 experiments with results favouring control and of
these, 9 reported volume ratios between 0.9 and 1 (Fig 2c). Egger regression was again consitent
with publication bias (t = 8.772, p<0.001; Fig 2d) and Trim and Fill analysis suggests the pres-
ence of 38 ‘missing studies’ (red plots, Fig 2c). After inclusion of these imputed missing studies
the adjusted global efficacy estimate was reduced from 3.07 to 1.77 (95%CI 1.46–2.14). For
survival studies, the funnel plot did not show any obvious asymmetry (Fig 2e), although the
Meta-Analysis of Trastuzumab in Preclinical Breast Cancer
PLOS ONE | DOI:10.1371/journal.pone.0158240 July 27, 2016 5 / 17
presence of publication bias was suggested by a positive intercept on Egger regression
(t = 5.340, p<0.001; Fig 2f). Trim and fill did not impute any missing studies for survival data.
Importantly, we would expect some of the studies reported here to be neutral. For instance,
some studies tested effciacy in cells known to have limited or no sensitivity to trastuzumab.
The presence of such studies is therefore likely to lead to an underestimation of the scale of
publication bias.
We have performed a cumulative meta-analysis for tumour volume to assess whether earlier
studies might have been more influential in decisions relating to clinical trial design. Plotting
global efficacy estimate for all studies published up to and including any given year shows a
steady trend for values to become more conservative with time, with for instance a global effi-
cacy estimate of 10.4 (4.01–27.1) in 2000 (Fig 3). This suggests a possible overestimation of effi-
cacy during the earlier years of trastuzumab research, which may be due to differences in study
design or quality measures. An alternative explanation would be if early studies tested efficacy
in situations where we would expect it to be higher, for instance using tumour cell lines more
sensitive to trastuzumab, or with intratumoural injection of drug. However, when we limit the
analysis to tumour cell lines graded as ++ or +++ we see the same non-significant trend of
decline in efficacy (S1 Fig)
Fig 1. PRISMA flowchart of study selection. The first search was performed on 4 July 2013, using the terms relating to (breast tumor OR breast cancer)
AND (trastuzumab OR Herceptin) (See S1 Table). On 18 September 2014, we added three further terms to expand the search with previous names of
trastuzumab: (breast tumor OR breast cancer) AND ("rhuMAb HER2" OR "Anti-p185HER2 Monoclonal Antibody" OR "muMAb 4D5”).
doi:10.1371/journal.pone.0158240.g001
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Fig 2. Evaluation of study quality and publication bias. (A) Quality score is associated with between-study
heterogeneity tumour volume studies, with a trend for higher quality studies to report smaller effect sizes (χ2 = 1373,
df = 6, p<0.00385). (B) Randomized studies were associated with smaller tumour volume reductions than non-
randomised studies (χ2 = 68.1, df = 1, p<0.00385). (C and D) Both funnel plot and Egger regression indicate a
presence of publication bias in tumour volume data (t = 8.772, p<0.001). Trim and Fill analysis added 38 ‘missing’
studies, with a sizeable reduction in global efficacy estimate (red plots). (E and F) For survival studies, funnel plot
does not show any obvious asymmetry, but Egger regression suggests a publication bias (t = 8.772, p<0.001). The
grey bands in A and B represent global 95% confidence intervals; columns represent mean ± 95%CI and column
width a measure of number of comparisons within each stratum; the number of comparisons is included at the base
of each column. Dotted lines in C and E represent global estimates of efficacy before (grey) and after (red) Trim and
fill analysis. Dotted lines in D and F represent 95%CI of the regression. The vertical solid lines in A, C, D and F
represent the level of neutral treatment effect.
doi:10.1371/journal.pone.0158240.g002
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Animal and tumour models
The experimental breast cancer tumour models fell into three broad categories: tumour xeno-
graft inoculation (146/158 volume studies, 11/11 survival studies), tumours induced using
mouse mammary tumour virus (MMTV, 10/158), oncomice with a genetic predisposition to
develop spontaneous tumours (1/158); and in 1 experiment the type of tumour was unclear.
Efficacy was higher in experiments using oncomice and tumours induced by MMTV than
those using xenografts (χ2 = 291, df = 3, p<0.00385). We observed 24 different tumour
xenograft models, of which the BT-474 cell line was the most commonly used in both tumor
volume (53/146) and survival studies (5/11). The specific xenograft model used were associ-
ated with a significant proportion of the observed heterogeneity in this group (χ2 = 4416,
df = 23, p<0.00385. Fig 4a) and the MDA-MB-453 model appeared to be most sensitive to
trastuzumab.
Tumours with augmented HER2 expression were commonly used (142/158 volume experi-
ments, 11/11 survival). Overexpression of HER2 was linked to a better outcome (χ2 = 160,
df = 1, p<0.00385, Fig 4b) when compared to HER2 negative or low expression. Furthermore,
we found that studies reporting the use of tumour cells known to be trastuzumab-resistant in
vitro were associated with smaller effect sizes (χ2 = 1009, df = 1, p<0.00385). Tumours were
inoculated either subcutaneously (88/158 volume studies, 8/11 survival) or into mammary tis-
sue (66/158; 3/11), and there was a greater reduction in tumour volume with subcutaneous
inoculation than for tumours induced by intramammary inoculation (χ2 = 810, df = 2,
p<0.00385; Fig 4c).
All studies included in our analysis used mice to evaluate trastuzumab efficacy. Almost all
used mice with altered immune status (155/158 volume studies, 11/11 survival studies), most
frequently athymic mice (for both volume (93/158) and survival studies (7/11)), with the next
most common using severe combined immunodeficient (SCID) models (23/158 volume, 3/11
survival). These models differed in the observed efficacy (χ2 = 5130, df = 9, P<0.00385, Fig 4d),
Fig 3. Cumulative meta-analysis. Plotting cumulative global efficacy estimate with time shows a steady
trend for values to becomemore conservative with time. Plot size is representative of the number of studies,
values for which are included on the right hand side, and error bars represent the 95%CI of the mean.
doi:10.1371/journal.pone.0158240.g003
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Fig 4. Stratification by animal and tumour model characteristics. (A) The specific xenograft model used were associated with a significant
proportion of the between-study heterogeneity (χ2 = 4416, df = 23, P<0.00385). (B) Overexpression of HER2 in breast cancer tumours was
associated with greater efficacy (χ2 = 160, df = 1, P<0.00385). (C) A greater reduction in tumour volume was observed with subcutaneous inoculation
compared to intramammary route (χ2 = 810, df = 2, P<0.00385). (D) There is comorbidity related between-study heterogeneity (χ2 = 5130, df = 9,
P<0.00385). The more commonly used athymic and SCID mice were associated with lower efficacies. (E) A significant proportion of between-study
heterogeneity is accounted for by the tumour volume at treatment initiation, with a smaller treatment effect seen at either extreme (χ2 = 1042, df = 6,
P<0.00385). The grey bands represent global 95% confidence intervals; diamonds (A) and columns (B-E) represent mean±95%CI and diamond size
(A) column width (B-E) a measure of number of comparisons within each stratum; the number of comparisons is included inside the y-axis (A) and at
the base of each column (B-E). The solid lines in A, C and E represent the level of neutral treatment effect.
doi:10.1371/journal.pone.0158240.g004
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with athymic and SCID mice being associated with lower efficacies than animals with non-spe-
cific ‘immunocompromised’mice or Rag2-M phenotype and those with no reported comor-
bidity. We included ovarectomy within this comorbidity stratification and efficacy was higher
in athymic mice that were ovarectomized than in athymic mice that were not (see Fig 4d).
We used tumour volume at initiation of therapy as a surrogate for the delay to trastuzumab
treatment, stratifying studies into groups of 0–50, 51–100, 101–200, 201–300, 301–400 and
>400 mm3, as well as unknown. For studies providing this information, the majority started
treatment when tumour volume was between 51 and 300 mm3. A significant proportion of
between-study heterogeneity in volume data is accounted for by this stratification, with a
smaller treatment effect seen at either extreme (χ2 = 1042, df = 6, p<0.00385, Fig 4e). This
information was only available for 6 survival studies.
Treatment regimen
To study the influence of different trastuzumab dosing regimens we stratified studies by total
trastuzumab dose, by route of delivery and by tumour volume at treatment initiation as dis-
cussed above. We did not include treatment duration, administration frequency, number of
cycles or other treatment details because specifying optimal dosing regimens in animals was
not an aim of this study.
We stratified the total trastuzumab dose into groups of<11, 11–25, 26–50, 51–75, 76–100
and>100 mg/kg, as well as unknown. Higher doses of trastuzumab were associated with
greater efficacy (χ2 = 723, df = 6, P<0.00385, Fig 5a). We observed heterogeneity between dif-
ferent routes of trastuzumab delivery; intraperitoneal injection was most frequently used (130/
158 volume and 9/11 survival studies). While all were effective, the single study reporting sub-
cutaneous injection reported greater reductions in tumour volume than pooled estimates for
other routes (χ2 = 62, df = 3, p<0.00385, Fig 5b).
Around half of the studies concomitantly implanted intradermal sustained-release estradiol
pellets before xenograft inoculation (80/158 tumour volume studies, 4/11 survival studies), and
these found greater reduction of tumour volume (χ2 = 336, df = 1, p<0.00385, Fig 5c). We also
found that the choice of control was associated with between-study heterogeneity, in that stud-
ies reporting the use of non-functioning antibodies as control were associated with more con-
servative estimates of efficacy than those using vehicle or non-treated controls (χ2 = 956,
df = 3, P<0.00385, Fig 5d).
Discussion
In this review of 83 publications involving 169 experiments and 2076 animals, trastuzumab
monotherapy appears to reduce tumour volume and prolong survival in animals bearing breast
tumours. We have identified a large degree of between-study heterogeneity within the volume
dataset but not across the smaller number of survival studies; and we have identified a number
of features pertaining to both study quality and design that are associated with between-study
heterogeneity. We have identified the presence of publication bias in both datasets.
In the tumour volume dataset we have demonstrated substantial between-study heterogene-
ity; furthermore, all the variables we tested accounted for between-heterogeneity in stratified
meta-analysis. Our strategy is limited in its univariate nature, and does not account for covari-
ance between the variables. [22, 29]. Colinearity might be taken into account using multivariate
techniques such as a multi-variable meta-regression but this approach is seldom used in meta-
analyses of animal data and its validity in this context is not known. The stratification account-
ing for the largest degree of heterogeneity (and therefore the first candidate variable for a multi-
variable approach) was the tumour model used; the large number of models (27, of which 16
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were only used in 3 experiments or fewer) precludes multivariate analysis. We did not see
between-study heterogeneity in the analysis of survival experiments. This may be due to the
small number of studies, each of small size with low power, or may relate to limitations in the
analysis brought about by the absence of data denoting within-study variance [26]. Conse-
quently the results from our analysis should be considered hypothesis generating only and
must be interpreted with caution.
We believe the preclinical trastuzumab literature is at high risk of bias. Study quality is mod-
est, with a median score of 6 out of a possible 12 and no study met more than 9 checklist items.
Less than half the studies reported randomized group allocation and no studies reported the
blinded assessment of outcome or the use of a sample size calculation. We have observed lower
efficacy in those studies at lower risk of bias—namely studies achieving a higher quality score
and those randomizing—and this phenomenon is well documented in the preclinical neurosci-
ences literature [22, 23]. Furthermore there is considerable publication bias amongst both data-
sets with a grossly asymmetrical funnel plot for tumour volume data and positive Egger’s test
for both datasets. Even Trim and Fill, a conservative technique [30], led to an adjusted estimate
of efficacy almost 50% lower than the unadjusted figure, implying a large excess of small studies
reporting large efficacy in the published literature.
Fig 5. Stratification by trastuzumab treatment characteristics. Total trastuzumab dose (A. χ2 = 723, df = 6,
P<0.00385), route of drug delivery (B. χ2 = 62, df = 3, P<0.00385), cotreatment with oestradiol (C. χ2 = 336,
df = 1, P<0.00385) and the choice of control (D. χ2 = 956, df = 3, P<0.00385), accounted for significant
between-study variability in reduction of tumour volume. The grey band represents global 95% confidence
intervals; columns represent mean ± 95%CI and column width a measure of number of comparisons within
each stratum; the number of comparisons is included at the base of each column.
doi:10.1371/journal.pone.0158240.g005
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Optimising study quality is important as overstated results from low quality animal studies
can misinform decisions to proceed to clinical trial [31] and inaccurate conclusions from these
data will inevitably lead to unnecessary animal suffering. There is increasing awareness of this
phenomenon and quality is in general improving with time [32]. Nonetheless we believe that a
standardized report pattern including measures to reduce risk of bias must be widely adopted
for animal research to continue to be valid as a translational strategy [33]. An exemplar report-
ing framework is the ARRIVE guidelines [33, 34].
The first article evaluating the efficacy of trastuzumab on breast cancer animal model was
published in 1991 [35]. However, this article was not included in our analysis as the primary
outcome was tumour weight and was therefore did not meet our inclusion criteria. The first
positive clinical study of trastuzumab showed objective responses in 43 of 46 patients with
tumours overexpressing HER2 in 1996 [36]; but the earliest animal study included in our anal-
ysis was published in 1998. There is a trend for reported effect size to become more conserva-
tive with time, implying that the problem of overstated efficacy was larger at the very time
when this information was most likely to be applied to human trials. Efficacy estimates appear
to decrease in magnitude from 2001: this may coincide with attempts to characterise trastuzu-
mab resistance, a process utilising different animal models, dosing regimens and trastuzumab-
resistant xenografts [37].
There are several factors that may influence an experimenter’s choice of tumour model [38,
39]. We have found that this choice was the largest source of heterogeneity and, when taken
with similar findings in glioma studies [21, 23], makes model choice a major determinant of
study outcome in cancer studies. This was why we included a justification for tumour model
choice or the testing of two or more tumour models as a study quality criterion. BT-474 and
MCF-7 (HER2-transfected) were the most popular cell lines and these appeared to be amongst
the more trastuzumab-sensitive.
We have also shown that the use of immunocompromised mice is the defaultmodus ope-
randi for preclinical breast cancer studies. While this is clearly important for the successful
inoculation of xenografts it should be borne in mind that the immune system plays a key role
in the body’s response to cancer and contributes substantially to the therapeutic effects of
monoclonal antibodies, [40, 41] this will not be recapitulated in studies using immunodeficient
animals. Greater volume reduction was seen in tumours inoculated subcutaneously than those
into mammary fat pad. Since the host environment in the latter more accurately represents
that in human disease we recommend that future studies should adopt this approach where
possible.
As for control reagents, we noticed a slightly reduced efficacy in studies controlling with
antibody (mainly with non-specific immunoglobulin), compared to vehicle and untreated con-
trols. While it may be possible for non-functioning antibodies to modulate the body’s response
to tumour this observation may also reflect the association between study quality and outcome
alluded to above.
In human disease, amplification of HER2 is usually associated with worse prognosis in
breast cancer; and trastuzumab is generally more effective against tumours overexpressing
HER2 to a higher degree. It is therefore relevant to assess HER2 status in order to prognosticate
treatment [42, 43]. This is generally done by measuring HER2 gene copy number with in situ
hybridization (ISH) or immunohistochemistry (IHC) [5, 9]. In our analysis we dichotomised
HER2 expression status into negative, with expression reported as low or negative, and posi-
tive, with HER2 overexpressed, observing greater efficacy in tumours overexpressing HER2.
We had initially intended to compare efficacy between different degrees of HER2 overexpres-
sion, however we found that studies used a range of different methods to quantify this,
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including but not limited to IHC and ISH, and in 65 experiments the degree of HER2 overex-
pression was not stated. Therefore this stratification was not possible.
The timing and dosage of treatment for any condition are inherently important and a wide
range of nuanced regimens were reported in the literature. However, characterizing details of
this were not the primary aims of this study. We have included analyses of total dose and delay
to treatment to gain a superficial insight into the regimens used and to give some simple com-
parisons between types. We have observed what seems to be a dose-response relationship with
trastuzumab although side effect profile has not been accounted for due to the lack of informa-
tion reported in the studies. Tumour volume reduction was relatively consistent with moderate
tumour initial volumes, with lower efficacy with larger tumours. To go further than this would
require prospective experiments directly comparing specific treatment regimens at various
stages of disease. Animal studies in general used intraperitoneal drug delivery, differing from
the intravenous route favoured in clinical practice. We saw greater efficacy in the single study
reporting subcutaneous delivery; subcutaneous administration has been tested in humans with
the advantage of convenience [44, 45], although there may be more serious adverse effects than
with intravenous delivery [46].
Hormone level plays an essential role in initiation, promotion, and progression of breast
cancer [47, 48]. Estrogen is required for the normal development of the mammary gland and is
predominantly produced in the ovary. Several studies reported the use of ovarectomy to simu-
late the postmenopausal, oestrogen-deplete, state. In these studies all animals were also athymic
and trastuzumab efficacy was greater in this group than in the athymic (non-ovarectomized)
animals (see Fig 4d and S2 Table). There is some evidence from animal models showing that
estrogens are breast carcinogens [49, 50] and when inoculating tumour xeongrafts, concordant
oestrogen delivery could increase the chance of tumour growth [51]. Estrogen was used as a
cotreatment in about half of the comparisons in our analyses while establishing breast cancer
model, mostly via a subcutaneous injection of sustained release estradiol less than a week prior
to tumour cell inoculation. Cotreatment resulted a higher efficacy in tumour volume studies.
This may reflect variations in tumour model or the fact that tumours co-expressing HER2 and
estrogen receptors are associated with a better outcome than those expressing HER2 alone [52]
To summarise, we have found trastuzumab to be effective in animal breast cancer models
across a range of experimental circumstances, correlating with clinical experience. There is evi-
dence to suggest this literature is at high risk of bias, through the presence of publication bias and
low prevalence of randomization and blinding. We have also defined a number of study design
features that appear to affect the perceived efficacy of trastuzumab. This meta-analysis is of course
limited, especially in the context of low-quality underlying data and the likely presence of colinear-
ity, so these results should be interpreted with caution.We hope that our conclusions may help to
streamline future research in experimental breast cancer and in the wider preclinical setting.
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